Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide receptor radionuclide therapy uptake-response study in somatostatin receptor-positive tumors
2015-005546-63Phase 2Completed
- Sponsor
- Santa Maria Nuova
- Start
- Jan 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate and yttrium (90Y) edotreotide in apudoma (NET), thyroid cancer, bronchial carcinoma and 1 more, sponsored by Santa Maria Nuova. Started Jan 2021; status: completed.
02
Drugs
lutetium Lu 177 dotatateyttrium (90Y) edotreotide
03
Conditions
apudoma (NET)thyroid cancerbronchial carcinomameningioma
Beyond the preview
Go deeper on 2015-005546-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005546-63.